Skip to content
Triangle logo TriangleGet started
← Study library

NCT00720083 · REGISTRY CONDITION SEARCH

Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2015-11-17

RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemotherapy together with radiation therapy is more effective with or without vandetanib in treating patients with head and neck cancer. PURPOSE: This randomized phase II trial is studying giving chemotherapy together with radiation therapy to see how well it works compared with giving chemotherapy and radiation therapy together with vandetanib in treating patients with high-risk stage III or stage IV head and neck cancer.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Disease-free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed squamous cell carcinoma of the head and neck, including any of the following subtypes: * Oral cavity * Oropharynx * Larynx * Hypopharynx * Stage III or IV disease (no distant metastases) * No cancer of the lip, nasopharynx, or sinuses * Must have undergone gross total resection\* (with curative intent) within 3-6 weeks of registration, with pathology demonstrating 1 or more of the following risk factors: * Histologic extracapsular nodal extension * Invasive cancer seen on microscopic evaluation of the resection margin, when all visible tumor has been removed NOTE: \*Tonsillar cancer patients who undergo transoral excision of all gross tumor are eligible if the patient has formal neck dissection confirming histologic extracapsular nodal extension PATIENT CHARACTERISTICS: Inclusion criteria: * Zubrod performance status 0-1 * ANC (absolute neutrophil count) ≥ 2,000/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 8.0 g/dL (transfusion or other intervention to achieve this level allowed) * Total bilirubin normal * AST (aspartate aminotransferase) or ALT (alanine amino transferase) ≤ 2 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 2.5 times ULN * Serum creatinine ≤ 1.5 mg/dL * Creatinine clearance ≥ 60 mL/min * Glucose ≥ 40 mg/dL AND ≤ 250 mg/dL * Sodium ≥ 130 mmol/L AND ≤ 155 mmol/L * Magnesium ≥ 0.9 mg/dL AND ≤ 3 mg/dL (supplementation allowed) * Potassium ≥ 4 mmol/L AND ≤ 6 mmol/L (supplementation allowed) * Serum calcium (ionized or adjusted for albumin) ≥ 7 mg/dL AND ≤ 12.5 mg/dL (supplementation allowed) * QTc (corrected QT interval) interval ≥ 480 msec must have 2 additional EKGs ≥ 24 hrs apart and the average QTc from the 3 screening EKGs must be \< 480 msec * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 60 days after completion of study treatment * May not donate blood during the study or for 3 months after last dose of vandetanib Exclusion criteria: * Other simultaneous primary cancer * Prior invasive malignancy (except nonmelanoma skin cancer) unless disease free for a minimum of 3 years with the exception of the following: * Carcinoma in situ of the cervix * Adequately treated basal cell or squamous cell carcinoma of the skin * Untreated or treated low-risk prostate cancer (defined as clinical or pathologic T1c, N0 M0, PSA (prostate-specific antigen) \< 10, Gleason \< 7, \< 50% of the total cores positive for cancer) * Severe, active co-morbidity, defined as follows: * Clinically significant cardiovascular event (e.g., myocardial infarction, superior vena cava syndrome, or New York Heart Association class II-IV) or presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia within the past 3 months * Unstable angina and/or congestive heart failure requiring hospitalization within the past 3 months * Transmural myocardial infarction within the past 3 months * History of arrhythmia (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTCAE \[Common Terminology Criteria for Adverse Events\] grade 3), or asymptomatic sustained ventricular tachycardia * Patients with atrial fibrillation, controlled on medication, are eligible * Presence of left bundle branch block * Previous history of QTc prolongation as a result from other medication that required discontinuation of that medication * Congenital long QTc syndrome or first degree relative with unexplained sudden death under 40 years of age * QTc with Bazett's correction that is unmeasurable or ≥ 480 msec on screening EKG * Patients who are receiving a drug that has a risk of QTc prolongation are not eligible if QTc is ≥ 460 msec * Hypertension (systolic blood pressure \[BP\] \> 160 mm Hg or diastolic BP \> 100 mm Hg) not controlled by medical therapy * Diarrhea ≥ grade 1 (increase of \< 4 stools per day over baseline or mild increase in ostomy output compared to baseline) * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within the past 30 days * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects * Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC (Center for Disease Control) definition (no HIV testing is required for study entry) * Prior allergic reaction to cisplatin or vandetanib or derivatives similar to these drugs PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior systemic chemotherapy for this disease (prior chemotherapy for a different cancer allowed) * No prior radiotherapy to the head and neck area that would result in overlap of radiotherapy fields * More than 30 days since prior investigational agents * More than 3 weeks since prior major surgery and recovered * More than 2 weeks since prior and no concurrent medications that induce Torsades de Pointes * More than 2 weeks since prior and no concurrent known potent inducers of CYP3A4 (Cytochrome P450 3A4), including rifampicin, phenytoin, carbamazepine, barbiturates, and Hypericum perforatum (St. John wort) * No concurrent medication that may cause QTc prolongation
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: cisplatin
    2. Radiation: radiation therapy
    label
    RT + Cisplatin
    type
    ACTIVE_COMPARATOR
  2. description
    Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: cisplatin
    2. Drug: vandetanib
    3. Radiation: radiation therapy
    label
    RT + Cisplatin + Vandetanib
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. RT + Cisplatin
    2. RT + Cisplatin + Vandetanib
    description
    Given IV
    name
    cisplatin
    type
    DRUG
  2. arm Group Labels
    1. RT + Cisplatin + Vandetanib
    description
    Given orally
    name
    vandetanib
    type
    DRUG
  3. arm Group Labels
    1. RT + Cisplatin
    2. RT + Cisplatin + Vandetanib
    description
    Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
    name
    radiation therapy
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
34
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.
    measure
    Disease-free Survival
    time Frame
    From randomization to date of failure (local, regional, or distant progression, or death) or last follow-up. Analysis occurs after 78 failures have been reported.
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemotherapy together with radiation therapy is more effective with or without vandetanib in treating patients with head and neck cancer. PURPOSE: This randomized phase II trial is studying giving chemotherapy together with radiation therapy to see how well it works compared with giving chemotherapy and radiation therapy together with vandetanib in treating patients with high-risk stage III or stage IV head and neck cancer.
detailed Description
OBJECTIVES: Primary * To screen for an indication that the addition of vandetanib to chemoradiotherapy may prolong disease-free survival as compared to a combination of chemoradiotherapy in patients with resected, high-risk stage III or IV head and neck squamous cell carcinoma. Secondary * To determine whether this treatment regimen can be delivered safely and successfully following surgical resection for advanced head and neck cancer. * To estimate the locoregional progression, distant metastasis, and overall survival rates for patients treated with this regimen. * To examine the distribution of selected biomarkers that may include but are not limited to EGFR (epidermal growth factor receptor, total and phosphorylated), E-cadherin, pMAPK (phosphorylated mitogen-activated protein kinase), pAKT, Stat-3 (signal transducer and activator of transcription 3), Ki-67, COX-2 (cyclooxygenase 2), and cyclin B1 (G2/mitotic-specific cyclin-B1)expression in this group of patients and to explore the potential correlation between these markers with the ultimate treatment outcome OUTLINE: This is a multicenter study. Patients are stratified according to Zubrod performance status (0 vs 1) and primary site of disease (oral cavity/hypopharynx vs larynx vs oropharynx, HPV+ (human papillomavirus positive) vs oropharynx, HPV- (human papillomavirus negative)). Patients are randomized to 1 of 2 arms. * Arm I: Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. * Arm II: Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. In both arms, treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Tissue samples from all patients are collected and reviewed. Tissue from patients with oropharyngeal carcinoma is analyzed for human papillomavirus. After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 4 years, and then annually thereafter.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6804f3f433c30b49ad01
      requested nct id
      NCT00720083
      primary nct id
      NCT00720083
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      eb4f3df031adcf6b1b46701d4ee0b4d72607aee2842de9ed2c937ff3a739428f
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6804f3f433c30b49ad01
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00720083
      occurrences
      1. context exact
        NCT00720083
        end
        11
        exact text
        NCT00720083
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/92/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e6f1bdf6425993a67b8d21920b89dd2d9b83fd5657071cddf4ebb64d4758bf65
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-9feed8c22d764d180461
      requested nct id
      NCT00720083
      primary nct id
      NCT00720083
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      ef14a5d7953b4fc2ba554dc8d084a1b9251d9d76f9be30bf56680a7cf99346cd
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-9feed8c22d764d180461
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00720083
      occurrences
      1. context exact
        NCT00720083
        end
        11
        exact text
        NCT00720083
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/129/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e6f1bdf6425993a67b8d21920b89dd2d9b83fd5657071cddf4ebb64d4758bf65

    Preserved source evidence · Not medical advice